BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| azithromycin,[CFS] - Chlamydia pneumoniae |
📓
In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother ) Vol: 43 Issue 9 Pages: 2268-72 Pub: 1999 Sep Epub: Authors Kutlin A , Roblin PM , Hammerschlag MR , Html Article Publication |
| azithromycin,[CFS] - Chlamydia pneumoniae |
📓
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria. The Journal of antimicrobial chemotherapy (J Antimicrob Chemother ) Vol: 80 Issue 2 Pages: 334-346 Pub: 2025 Feb 3 Epub: Authors Assefa GM , Roberts JA , Aslan AT , Mohammed SA , Sime FB , Html Article Publication |
| azithromycin,[CFS] - Chlamydia pneumoniae |
📓
Azithromycin: a new 15-membered macrolide. The Japanese journal of antibiotics (Jpn J Antibiot ) Vol: 54 Suppl A Issue Pages: 70-6 Pub: 2001 Feb Epub: Authors Treadway G , |
| azithromycin,[CFS] - Chlamydia pneumoniae |
📓
Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. The Journal of infectious diseases (J Infect Dis ) Vol: 183 Issue 2 Pages: 232-238 Pub: 2001 Jan 15 Epub: 2000 Dec 13 Authors Rothstein NM , Quinn TC , Madico G , Gaydos CA , Lowenstein CJ , Publication |
| azithromycin,[CFS] - Chlamydia pneumoniae |
📓
Impact of azithromycin, doxycycline and redox-active small molecules on amoxicillin-induced Chlamydia pneumoniae persistence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother ) Vol: 167 Issue Pages: 115451 Pub: 2023 Nov Epub: 2023 Sep 8 Authors Taavitsainen-Wahlroos E , Reigada I , Sulmona I , Hanski L , Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
